So are CPH (phase 2 clinical trial), VIT, LGP and I think another one I can't remember. But EMD is easily my pick of the bunch.
MKT The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint
Week 45 Wrap: Combat sports usher in Trump 2.0 – or is it male insecurity?; RBA boring; Propane suggests China alive
